Oxycodone ER releases a blue dye and nasal irritant when manipulated to help identify illicit users and discourage misuse of the drug. Intellipharma designed the drug as an abuse-deterrent version of Purdue Pharma’s opioid, OcyContin.
The FDA rejected OxyCodone ER in its current form and requested additional proof of the drug’s abuse-deterrent qualities, as well as more information on the drug’s blue dye. An FDA advisory panel in July voted 22-1 against approving the drug, with some experts expressing concerns about the dye’s possible toxicity.
Intellipharma has at least one year to provide the FDA with the requested information. The drugmaker said the regulatory decision will not affect Oxycodone ER’s marketing timeline, according to Reuters.
More articles on opioids:
7 ways clinicians can help reduce opioid misuse and addiction
CVS is now limiting opioid prescriptions
Opioid overdose deaths chip away at US life expectancy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
